VIVUS Announces Date of 2019 Annual Meeting
February 04 2019 - 4:00PM
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical
company, today announced that the Company will hold its 2019 Annual
Meeting of Stockholders (the “2019 Annual Meeting”) on June 5,
2019. Because the 2019 Annual Meeting will be held more than 30
days from the anniversary date of the 2018 Annual Meeting of
Stockholders, the Company is informing its stockholders of the
revised deadlines for proposals, director nominations and other
related matters for consideration at the 2019 Annual Meeting.
Pursuant to Rule 14a‑8 under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), stockholders
may present proper proposals for inclusion in the 2019 Proxy
Statement and for consideration at the Company’s 2019 Annual
Meeting. To be eligible for inclusion in the 2019 Proxy Statement,
a proposal must be received by the Company no later than February
18, 2019 and must otherwise comply with Rule 14a‑8.
In addition, under the Company’s Amended and
Restated Bylaws, as further amended, in order to nominate a
director or bring any other business before the stockholders at the
2019 Annual Meeting that will not be included in the 2019 Proxy
Statement, the proposal must be received by the Company’s Corporate
Secretary on or between February 5, 2019 and March 7, 2019.
All stockholder proposals, director nominations
and other related matters must comply, as applicable, with Delaware
law, the rules and regulations under the Exchange Act and the
Company’s Amended and Restated Bylaws, as further amended.
About VIVUS
VIVUS is a biopharmaceutical company committed
to the development and commercialization of innovative therapies
that focus on advancing treatments for patients with serious unmet
medical needs. For more information about the Company, please
visit www.vivus.com.
Forward-Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” “intend,” “likely,”
“may,” “plan,” “potential,” “predict,” “opportunity” and “should,”
among others. There are a number of factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. VIVUS does not undertake an obligation
to update or revise any forward-looking statements. Investors
should read the risk factors set forth in VIVUS’ Form 10-K for the
year ended December 31, 2017 as filed on March 14, 2018, and as
amended by the Form 10-K/A filed on April 26, 2018, and periodic
reports filed with the Securities and Exchange Commission.
VIVUS,
Inc. |
|
Investor
Relations: Lazar Partners |
Mark Oki |
|
David Carey |
Chief Financial
Officer |
|
Managing Director |
oki@vivus.com |
|
dcarey@lazarpartners.com |
650-934-5200 |
|
212-867-1768 |
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Apr 2023 to Apr 2024